Tyra Biosciences (TYRA) Jefferies London Healthcare Conference 2024 summary

Company overview and lead programs

• Focuses on small molecule precision medicines, with a lead oral FGFR3 selective inhibitor showing strong efficacy and safety in metastatic urothelial cancer.

• Achondroplasia study cleared by FDA, with plans to treat children soon; also developing FGFR2 and FGFR4 inhibitors.

Clinical data and differentiation

• Achieved a 54.5% response rate in metastatic urothelial cancer, surpassing erdafitinib's 35%.

• Demonstrated significant reduction in FGFR1/2-related toxicities, with most adverse events being low grade.

• ALT/AST increases were low grade and manageable, especially at lower doses for achondroplasia and NMIBC.

Safety and efficacy profile

• No treatment-related adverse events at 40 mg in children; minimal events at 60 mg.

• No evidence of cumulative liver enzyme effects at lower doses over a year.

• Hyperphosphatemia rates were low and mostly within normal limits, with only one patient requiring a binder.